Quick Answer
HERON THERAPEUTICS, INC. /DE/ reported Net Income Loss of -$20.20 million for the year ending 2025.
- HERON THERAPEUTICS, INC. /DE/ showed a decrease of -48.7% in Net Income Loss from 2024 to 2025.
- This data is from HERON THERAPEUTICS, INC. /DE/'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2015: -$31.24 million | Q1 2016: -$33.45 million | Q2 2016: -$43.23 million | Q3 2016: -$48.51 million | Q4 2016: -$47.96 million | Q1 2017: -$50.33 million | Q2 2017: -$42.80 million | Q3 2017: -$41.87 million | Q4 2017: -$62.49 million | Q1 2018: -$52.27 million | Q2 2018: -$38.67 million | Q3 2018: -$38.35 million | Q4 2018: -$49.56 million | Q1 2019: -$63.01 million | Q2 2019: -$50.22 million | Q3 2019: -$33.60 million | Q4 2019: -$57.92 million | Q1 2020: -$51.58 million | Q2 2020: -$55.19 million | Q3 2020: -$58.23 million | Q4 2020: -$62.28 million | Q1 2021: -$52.61 million | Q2 2021: -$61.02 million | Q3 2021: -$52.41 million | Q1 2022: -$63.89 million | Q2 2022: -$56.36 million | Q3 2022: -$41.91 million | Q1 2023: -$32.77 million | Q2 2023: -$42.06 million | Q3 2023: -$25.01 million | Q1 2024: -$3.16 million | Q2 2024: -$9.24 million | Q3 2024: -$4.85 million | Q1 2025: $2.64 million | Q2 2025: -$2.38 million | Q3 2025: -$17.50 million.
- Over the full 17 years of available data (2009 to 2025), HERON THERAPEUTICS, INC. /DE/'s Net Income Loss has declined by 101.4%.
- Historical annual values: Fiscal year 2025: -$20.20 million | Fiscal year 2024: -$13.58 million | Fiscal year 2023: -$110.56 million | Fiscal year 2022: -$182.02 million | Fiscal year 2021: -$220.68 million | Fiscal year 2020: -$227.28 million | Fiscal year 2019: -$204.75 million | Fiscal year 2018: -$178.84 million | Fiscal year 2017: -$197.48 million | Fiscal year 2016: -$173.14 million | Fiscal year 2015: -$97.59 million | Fiscal year 2014: -$76.37 million | Fiscal year 2013: -$55.28 million | Fiscal year 2012: -$23.35 million | Fiscal year 2011: -$11.81 million | Fiscal year 2010: -$7.35 million | Fiscal year 2009: -$10.03 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: